John Tsai
As a child, John Tsai used to take apart his older brother’s toys to see how they were made. This curiosity propelled him into a career first as an electrical engineer, and then on to medical school and into drug development. Last year he joined Novartis as head of global drug development and Chief...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Drug discovery 2019-06, Vol.18 (6), p.414-414 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 414 |
|---|---|
| container_issue | 6 |
| container_start_page | 414 |
| container_title | Nature reviews. Drug discovery |
| container_volume | 18 |
| creator | Mullard, Asher |
| description | As a child, John Tsai used to take apart his older brother’s toys to see how they were made. This curiosity propelled him into a career first as an electrical engineer, and then on to medical school and into drug development. Last year he joined Novartis as head of global drug development and Chief Medical Officer, after nearly 20 years at Pfizer, Bristol-Myers Squibb and Amgen. At Novartis he is now overseeing, amongst other things, the company’s embrace of advanced therapies — including its gene therapy Zolgensma for spinal muscular atrophy. He spoke with
Asher Mullard
about applying an engineering mindset to drug development, the opportunities for operational efficiencies in clinical science and the future of advanced therapies at Novartis.
As a child, John Tsai used to take apart his older brother’s toys to see how they were made. This curiosity propelled him into a career first as an electrical engineer, and then on to medical school and into drug development. Last year he joined Novartis as head of global drug development and Chief Medical Officer, after nearly 20 years at Pfizer, Bristol-Myers Squibb and Amgen. At Novartis he is now overseeing, amongst other things, the company’s embrace of advanced therapies — including its gene therapy Zolgensma for spinal muscular atrophy. He spoke with Asher Mullard about applying an engineering mindset to drug development, the opportunities for operational efficiencies in clinical science and the future of advanced therapies at Novartis. |
| doi_str_mv | 10.1038/d41573-019-00089-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2235068110</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A623720411</galeid><sourcerecordid>A623720411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-f3745b37a141000bc5a6e9d7d87cbac1debc911544bcf34a5341afe091ae29de3</originalsourceid><addsrcrecordid>eNp9kctOwzAQRS0EoqXwAywQEhs2KR6PYyfLquKpSmzK2nIcp6TKo9jNgr_HJaU8hCovbI3PvTOjS8g50DFQTG5yDrHEiEIaUUqTNBIHZAhc8ghkwg93bykG5MT7JaUgQLJjMkAAQUN9SIZP7WtzOfe6PCVHha68PdveI_JydzufPkSz5_vH6WQWGc5gHRUoeZyh1MAhdM1MrIVNc5kn0mTaQG4zkwLEnGemQK5j5KALS1PQlqW5xRG57n1Xrn3rrF-ruvTGVpVubNt5xRjGVCQQVhyRqz_osu1cE6ZTCIhUUpniPip4cS6C3w9qoSuryqZo106bTWs1EQwloxwgUON_qHByW5embWxRhvovAesFxrXeO1uolStr7d4VULVJSfUpqZCS-kxJiSC62E7cZbXNd5KvWAKAPeDDV7Ow7nulPbYfzDaWcw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2234463503</pqid></control><display><type>article</type><title>John Tsai</title><source>SpringerLink Journals</source><source>Nature</source><creator>Mullard, Asher</creator><creatorcontrib>Mullard, Asher</creatorcontrib><description>As a child, John Tsai used to take apart his older brother’s toys to see how they were made. This curiosity propelled him into a career first as an electrical engineer, and then on to medical school and into drug development. Last year he joined Novartis as head of global drug development and Chief Medical Officer, after nearly 20 years at Pfizer, Bristol-Myers Squibb and Amgen. At Novartis he is now overseeing, amongst other things, the company’s embrace of advanced therapies — including its gene therapy Zolgensma for spinal muscular atrophy. He spoke with
Asher Mullard
about applying an engineering mindset to drug development, the opportunities for operational efficiencies in clinical science and the future of advanced therapies at Novartis.
As a child, John Tsai used to take apart his older brother’s toys to see how they were made. This curiosity propelled him into a career first as an electrical engineer, and then on to medical school and into drug development. Last year he joined Novartis as head of global drug development and Chief Medical Officer, after nearly 20 years at Pfizer, Bristol-Myers Squibb and Amgen. At Novartis he is now overseeing, amongst other things, the company’s embrace of advanced therapies — including its gene therapy Zolgensma for spinal muscular atrophy. He spoke with Asher Mullard about applying an engineering mindset to drug development, the opportunities for operational efficiencies in clinical science and the future of advanced therapies at Novartis.</description><identifier>ISSN: 1474-1776</identifier><identifier>EISSN: 1474-1784</identifier><identifier>DOI: 10.1038/d41573-019-00089-6</identifier><identifier>PMID: 31160776</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/154 ; 631/208/2489/201 ; Advantages ; An Audience With ; Clinical trials ; Drug development ; Electrical engineering ; Engineers ; Gene therapy ; Interviews ; Manufacturing ; Medical colleges ; Pharmaceutical industry</subject><ispartof>Nature reviews. Drug discovery, 2019-06, Vol.18 (6), p.414-414</ispartof><rights>Springer Nature Limited 2019</rights><rights>COPYRIGHT 2019 Nature Publishing Group</rights><rights>Nature 2019.</rights><rights>Copyright Nature Publishing Group Jun 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/d41573-019-00089-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/d41573-019-00089-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31160776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mullard, Asher</creatorcontrib><title>John Tsai</title><title>Nature reviews. Drug discovery</title><addtitle>Nat Rev Drug Discov</addtitle><addtitle>Nat Rev Drug Discov</addtitle><description>As a child, John Tsai used to take apart his older brother’s toys to see how they were made. This curiosity propelled him into a career first as an electrical engineer, and then on to medical school and into drug development. Last year he joined Novartis as head of global drug development and Chief Medical Officer, after nearly 20 years at Pfizer, Bristol-Myers Squibb and Amgen. At Novartis he is now overseeing, amongst other things, the company’s embrace of advanced therapies — including its gene therapy Zolgensma for spinal muscular atrophy. He spoke with
Asher Mullard
about applying an engineering mindset to drug development, the opportunities for operational efficiencies in clinical science and the future of advanced therapies at Novartis.
As a child, John Tsai used to take apart his older brother’s toys to see how they were made. This curiosity propelled him into a career first as an electrical engineer, and then on to medical school and into drug development. Last year he joined Novartis as head of global drug development and Chief Medical Officer, after nearly 20 years at Pfizer, Bristol-Myers Squibb and Amgen. At Novartis he is now overseeing, amongst other things, the company’s embrace of advanced therapies — including its gene therapy Zolgensma for spinal muscular atrophy. He spoke with Asher Mullard about applying an engineering mindset to drug development, the opportunities for operational efficiencies in clinical science and the future of advanced therapies at Novartis.</description><subject>631/154</subject><subject>631/208/2489/201</subject><subject>Advantages</subject><subject>An Audience With</subject><subject>Clinical trials</subject><subject>Drug development</subject><subject>Electrical engineering</subject><subject>Engineers</subject><subject>Gene therapy</subject><subject>Interviews</subject><subject>Manufacturing</subject><subject>Medical colleges</subject><subject>Pharmaceutical industry</subject><issn>1474-1776</issn><issn>1474-1784</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kctOwzAQRS0EoqXwAywQEhs2KR6PYyfLquKpSmzK2nIcp6TKo9jNgr_HJaU8hCovbI3PvTOjS8g50DFQTG5yDrHEiEIaUUqTNBIHZAhc8ghkwg93bykG5MT7JaUgQLJjMkAAQUN9SIZP7WtzOfe6PCVHha68PdveI_JydzufPkSz5_vH6WQWGc5gHRUoeZyh1MAhdM1MrIVNc5kn0mTaQG4zkwLEnGemQK5j5KALS1PQlqW5xRG57n1Xrn3rrF-ruvTGVpVubNt5xRjGVCQQVhyRqz_osu1cE6ZTCIhUUpniPip4cS6C3w9qoSuryqZo106bTWs1EQwloxwgUON_qHByW5embWxRhvovAesFxrXeO1uolStr7d4VULVJSfUpqZCS-kxJiSC62E7cZbXNd5KvWAKAPeDDV7Ow7nulPbYfzDaWcw</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Mullard, Asher</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190601</creationdate><title>John Tsai</title><author>Mullard, Asher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-f3745b37a141000bc5a6e9d7d87cbac1debc911544bcf34a5341afe091ae29de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>631/154</topic><topic>631/208/2489/201</topic><topic>Advantages</topic><topic>An Audience With</topic><topic>Clinical trials</topic><topic>Drug development</topic><topic>Electrical engineering</topic><topic>Engineers</topic><topic>Gene therapy</topic><topic>Interviews</topic><topic>Manufacturing</topic><topic>Medical colleges</topic><topic>Pharmaceutical industry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mullard, Asher</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Drug discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mullard, Asher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>John Tsai</atitle><jtitle>Nature reviews. Drug discovery</jtitle><stitle>Nat Rev Drug Discov</stitle><addtitle>Nat Rev Drug Discov</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>18</volume><issue>6</issue><spage>414</spage><epage>414</epage><pages>414-414</pages><issn>1474-1776</issn><eissn>1474-1784</eissn><abstract>As a child, John Tsai used to take apart his older brother’s toys to see how they were made. This curiosity propelled him into a career first as an electrical engineer, and then on to medical school and into drug development. Last year he joined Novartis as head of global drug development and Chief Medical Officer, after nearly 20 years at Pfizer, Bristol-Myers Squibb and Amgen. At Novartis he is now overseeing, amongst other things, the company’s embrace of advanced therapies — including its gene therapy Zolgensma for spinal muscular atrophy. He spoke with
Asher Mullard
about applying an engineering mindset to drug development, the opportunities for operational efficiencies in clinical science and the future of advanced therapies at Novartis.
As a child, John Tsai used to take apart his older brother’s toys to see how they were made. This curiosity propelled him into a career first as an electrical engineer, and then on to medical school and into drug development. Last year he joined Novartis as head of global drug development and Chief Medical Officer, after nearly 20 years at Pfizer, Bristol-Myers Squibb and Amgen. At Novartis he is now overseeing, amongst other things, the company’s embrace of advanced therapies — including its gene therapy Zolgensma for spinal muscular atrophy. He spoke with Asher Mullard about applying an engineering mindset to drug development, the opportunities for operational efficiencies in clinical science and the future of advanced therapies at Novartis.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31160776</pmid><doi>10.1038/d41573-019-00089-6</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1776 |
| ispartof | Nature reviews. Drug discovery, 2019-06, Vol.18 (6), p.414-414 |
| issn | 1474-1776 1474-1784 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2235068110 |
| source | SpringerLink Journals; Nature |
| subjects | 631/154 631/208/2489/201 Advantages An Audience With Clinical trials Drug development Electrical engineering Engineers Gene therapy Interviews Manufacturing Medical colleges Pharmaceutical industry |
| title | John Tsai |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A07%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=John%20Tsai&rft.jtitle=Nature%20reviews.%20Drug%20discovery&rft.au=Mullard,%20Asher&rft.date=2019-06-01&rft.volume=18&rft.issue=6&rft.spage=414&rft.epage=414&rft.pages=414-414&rft.issn=1474-1776&rft.eissn=1474-1784&rft_id=info:doi/10.1038/d41573-019-00089-6&rft_dat=%3Cgale_proqu%3EA623720411%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2234463503&rft_id=info:pmid/31160776&rft_galeid=A623720411&rfr_iscdi=true |